On August 3, 2026, CMS filed the FY2027 Hospice Wage Index and Payment Rate Update final rule (CMS-1851-F) with the Federal Register. It raises hospice payments by 2.3%, an estimated $755 million in aggregate, effective October 1, 2026. Most owners read that as a modest bit of breathing room. Buyers read it as something else: a fresh, public scorecard on which hospices run a clean operation.
That matters right now because the phone is ringing again. The home health and hospice sector recorded 110 transactions in 2025 against 97 in 2024, and the fourth quarter alone produced 16 hospice deals, the highest quarterly count since late 2021 (Levin Associates and Mertz Taggart, 2026). Private equity activity across home-based care grew 53.6% year over year in 2025.
So when an owner asks us who buys hospice agencies, the honest answer is that the buyer universe is smaller and more identifiable than most people expect. There are roughly four groups. They pay differently, they behave differently after closing, and they want different things from your chart notes. This guide walks through each one, what they are paying as of August 2026, and what the FY2027 rule changes about how they look at you.
Who buys hospice agencies in 2026?
Hospice agencies are bought by four kinds of acquirers: private-equity-backed strategic platforms, pure financial sponsors building a new platform, publicly traded strategic operators, and regional operators making tuck-in acquisitions. As of August 2026, PE-backed strategics account for the largest share of closed deals by count, and roughly 41% of home health and hospice transactions this year involved private equity capital (Levin Associates, 2026).
The distinction that matters to you is not whether a buyer is “private equity.” Nearly all of them have sponsor capital somewhere in the structure. What matters is where you sit in their model: are you the platform they are building around, or the add-on they are bolting onto something they already own. That single fact drives your multiple more than almost anything else in the conversation.
Agencies with strong census stability, clean survey history, and a management team that runs without the owner tend to get platform treatment. Agencies with one location, a founder who signs every certification, and a referral base concentrated in two hospital systems tend to get add-on treatment. Both are sellable. They are not priced the same.
What are the four types of hospice buyers, and how do they differ?
The four buyer types differ in target size, what they underwrite, what they will pay, and how much changes at your agency after the deal closes. The table below reflects closed-deal patterns observed through the first half of 2026.
| Buyer type | Typical target | What they underwrite | Indicative EBITDA range | What changes after close |
|---|---|---|---|---|
| PE-backed strategic platform | $3M to $40M revenue, any structure | Geographic density, referral durability, compliance record | 6.0x to 11.0x | Back office consolidates, clinical leadership usually stays, billing moves to their system |
| Financial sponsor building a platform | $15M+ revenue, multi-site, management depth | Management team, scalability, EBITDA quality | 9.0x to 13.0x, premium assets above 14.0x | You become the acquirer; owner often rolls equity and stays 2 to 4 years |
| Public strategic operator | Varies widely; fills map gaps | Market share, licensure, CON position where applicable | 7.0x to 12.0x | Full integration into corporate systems and protocols |
| Regional operator (tuck-in) | $1M to $8M revenue, nearby | Census, staff retention, immediate cost overlap | 4.0x to 7.0x | Fastest integration; often the least disruption to daily care |
PE-backed strategic platforms
These are operating companies with sponsor money behind them. They already run hospices, they already have a compliance department, and they are buying you for density in a market they care about. They move quickly because they have done this before, and they will find problems in your documentation because they know exactly where to look.
Financial sponsors building a new platform
A sponsor without a hospice asset in the vertical is looking for a first platform, and platform deals carry the highest multiples in the market. They need management depth, because they are buying a team as much as a census. If you are the only person who can run the agency, you are not a platform, regardless of your revenue.
Public strategic operators
Names like BrightSpring, Pennant, Aveanna, Addus, and Chemed (VITAS) buy to fill specific geographic or service gaps. Their diligence is thorough and their timelines are governed by public-company reporting. They pay fairly for assets that fit the map and pass quickly for assets that do not.
Regional operators making tuck-ins
The quietest group and, for a lot of smaller agencies, the most realistic. A hospice 40 miles away that wants your census and your nurses can close faster than anyone, sometimes with seller financing. The multiple is lower. The certainty is often higher, and the disruption to your patients and staff is usually the smallest of the four.
Do private equity firms buy small hospice agencies?
Yes, private equity firms regularly buy small hospice agencies, almost always as add-on acquisitions to a platform they already own rather than as standalone investments. In 2025, private equity backers of home-based care completed 11 new platform investments and 32 add-on acquisitions, so add-ons outnumbered platforms roughly three to one (Levin Associates, 2026).
Practically, that means an agency in the $5M to $20M revenue range that provides geographic density is squarely in demand. Once a sponsor owns a platform, its economics improve every time it adds census in an adjacent market at a lower non-platform multiple. Your agency does not need to be large to be wanted. It needs to be adjacent and clean.
The sponsors most frequently named in hospice and home health transactions from 2024 through 2026 include Kinderhook Industries, Linden Capital Partners, Webster Equity Partners, Waud Capital, Revelstoke Capital Partners, Trive Capital, and Searchlight Capital. The clearest signal of how serious this capital is came on May 15, 2026, when Kinderhook closed its $1.1 billion take-private acquisition of Enhabit at $13.80 per share, roughly a 25% premium to the pre-announcement price. Enhabit operates about 250 home health locations and more than 115 hospice locations across 34 states (Home Health Care News, 2026).
A deal of that size does not stay contained. Every platform of that scale spends the following 24 months buying smaller agencies around its footprint. If you own a hospice within driving distance of an Enhabit market, you are on somebody’s list.
How much do buyers pay for a hospice agency?
As of August 2026, hospice agencies have generally traded between 4.0x and 13.0x EBITDA depending on scale and quality, with closed transactions in Q2 2026 clustering in the 9.0x to 13.0x range and premium platforms pricing above 14.0x (FOCUS Investment Banking and Hospice News, 2026). Smaller single-site agencies sit at the low end of that spread.
| Agency profile | Approximate revenue | Indicative EBITDA multiple | Primary value driver |
|---|---|---|---|
| Single site, low or volatile census | Under $3M | 4.0x to 6.0x | Census stability and licensure |
| Multi-site or strong single-state density | $3M to $12M | 5.0x to 7.0x | Referral diversity and staffing |
| Regional multi-state platform | $12M to $40M | 6.0x to 9.0x | Management depth and compliance record |
| Premium scale platform, strong HQRP scores, integrated palliative | $40M+ | 9.0x to 13.0x, select assets above 14.0x | Durable EBITDA and clean regulatory posture |
Two cautions on the numbers. First, revenue multiples circulate widely in hospice conversations and they are a rough screening tool at best. Buyers pivot to EBITDA the moment a letter of intent is drafted, and the gap between a revenue rule of thumb and a real EBITDA valuation is where most owner disappointment lives.
Second, the multiple is applied to adjusted EBITDA, and the adjustment conversation is where preparation pays. Owner compensation above market, personal expenses running through the agency, one-time legal costs, and non-recurring startup losses can all be added back, but only if the documentation supports them. Buyers discount add-backs they cannot verify.
Want a range for your own agency before you take the next call?
Run your numbers through our valuation calculator to see an indicative range based on your revenue, EBITDA, census, and payer mix. It takes a few minutes and costs nothing.
Does the FY2027 hospice final rule change what buyers will pay?
The FY2027 final rule does not change hospice multiples directly, but it changes what buyers can see about your operation before they ever ask you a question. The rule was posted to the Federal Register on August 3, 2026 and takes effect October 1, 2026.
Here is what CMS finalized in CMS-1851-F, per the agency’s own fact sheet (CMS, 2026):
- A 2.3% payment update for FY2027, an estimated $755 million increase in aggregate payments over FY2026.
- A hospice aggregate cap of $36,174.75 for the FY2027 cap year.
- A rate of -1.7% for hospices that fail to submit required quality data, calculated as the 2.3% update minus 4 percentage points.
- A HOPE assessment timeliness threshold of 90%, with submissions due within 30 days of a patient’s admission or discharge date.
- A new non-compliance icon on Medicare.gov Care Compare for hospices that miss reporting requirements, with public reporting no earlier than FY2028 using CY2026 submission data.
Read those last two together. A public icon flagging quality-reporting failure is a diligence finding that a buyer can pull up on a phone, without an NDA, before your banker has finished the introduction. Reporting discipline used to be an internal operations matter. Starting with this rule cycle, it becomes part of your public profile.
The cap deserves the same attention. Agencies running close to the aggregate cap have less headroom for long-stay patients, and buyers model cap exposure carefully because an overage is a repayment obligation that follows the license. If your cap utilization has been climbing, a buyer will find it, and the discussion will move to escrow.
The good news for an owner reading this in August 2026 is timing. The rule is effective October 1, and the CY2026 data that eventually shows up on Care Compare is being generated right now. There is a window to tighten submission timeliness before the record hardens.
What do hospice buyers check during diligence?
Hospice buyers check eligibility documentation, live discharge patterns, length-of-stay distribution, aggregate cap headroom, survey and audit history, referral concentration, quality-reporting timeliness, and how much of the operation depends on the owner personally. Compliance is the first gate, not the last.
That ordering has shifted over the past two years. Buyers have moved from growth-driven to quality-driven underwriting, and compliant hospice assets are genuinely in short supply. OIG and DOJ scrutiny of eligibility determinations, live discharge rates, and documentation patterns has made a clean record a pricing input rather than a formality (ION Analytics, 2026). Scarcity works in your favor if your file is clean.
The specific items that most often reduce a price or stall a deal:
- Thin eligibility documentation. Certifications and face-to-face encounters that do not clearly support terminal prognosis are the single most common finding.
- Live discharge rates outside the norm. Buyers benchmark this against regional peers and treat outliers as audit exposure.
- Length-of-stay concentration. A census weighted toward very long stays draws cap and eligibility questions at the same time.
- Referral concentration. If one facility or hospital system sends more than roughly 30% of admissions, buyers model what happens if that relationship ends at close.
- Owner-held relationships. Referrals that exist because of you personally are the hardest asset to transfer and the easiest for a buyer to discount.
- Staffing instability. High RN and aide turnover, or an interdisciplinary group that has churned recently, reads as census risk.
- Unresolved survey deficiencies. An open plan of correction will not necessarily kill a deal, but it will slow one and it will be priced.
None of these are unfixable. Most of them take 6 to 12 months of ordinary discipline, which is precisely why the owners who get the best outcomes start preparing well before they intend to sell.
How do you prepare a hospice agency for the buyers you actually want?
Preparing a hospice for sale is a seven-step sequence that takes most owners 6 to 12 months and is worth starting before you have decided to sell. The goal is simple: make the agency legible to a buyer, so that the price reflects what you built rather than what a buyer cannot verify.
- Fix quality-reporting timeliness first. Get HOPE submissions inside the 30-day window and hold the rate above 90%. This is the cheapest value protection available to you as of August 2026, and the FY2027 rule made it public.
- Clean the eligibility file. Audit a sample of certifications and face-to-face encounters against terminal prognosis documentation. Correct the process going forward before a buyer samples the same charts.
- Model your cap position. Calculate aggregate cap utilization for the current and prior cap years. If you are running close, understand why, and be ready to explain it.
- Normalize the financials. Build a clean adjusted EBITDA with every add-back supported by documentation. Separate personal expenses from agency expenses now, not during diligence.
- Diversify and document referrals. Move the top relationships from personal to institutional. Written agreements, named account owners on your team, and a tracked referral pipeline all transfer; a founder’s friendship does not.
- Build the layer below you. Confirm a clinical leader and an administrator who can run the agency without you in the building. Buyers pay a premium for a team and discount for a dependency.
- Get an independent valuation, then decide. A real range, built on your numbers, tells you whether the offers you are fielding are serious. Only after that does it make sense to choose which buyer type to approach.
Owners who run this sequence rarely regret it, even if they decide not to sell. Every step on the list also improves the agency’s margins and reduces its regulatory exposure while you continue to own it.
Should you sell to a strategic buyer or a PE-backed platform?
Sell to a PE-backed platform if you want the highest headline price and are willing to accept integration and a possible equity rollover; sell to a strategic operator or regional buyer if you want speed, certainty, and less disruption to your staff and patients. Neither choice is universally correct, and the right answer depends on what you want your life to look like 18 months after closing.
A few practical differences owners tell us mattered more than they expected:
- Equity rollover. Sponsors often ask sellers to roll 10% to 30% of proceeds into the new entity. That can be a genuine second payday, and it is also money still at risk. Understand the terms before you fall in love with the headline number.
- Earnout structure. A larger multiple with half the value in an earnout is not the same as cash at close. Ask what portion is guaranteed.
- Staff continuity. Regional and strategic buyers often keep the clinical team largely intact. Platform integrations more commonly consolidate back-office roles.
- Speed. A prepared regional buyer can close in a fraction of the time a sponsor needs for a first platform investment.
The way to make this a real choice rather than a reaction is to have more than one buyer at the table. An owner responding to a single unsolicited call has one option and no leverage. An owner running a confidential process with several qualified buyers can actually compare structures.
How long does a hospice sale take?
A hospice sale typically takes 6 to 10 months from preparation to close, and the change-of-ownership process with CMS and the state is what usually determines the back half of that timeline rather than the negotiation itself.
| Stage | Typical duration | What drives the timing |
|---|---|---|
| Preparation and valuation | 4 to 12 weeks | Financial cleanup, compliance review, add-back documentation |
| Confidential buyer outreach | 4 to 8 weeks | NDA-gated marketing to qualified buyers only |
| Offers and letter of intent | 3 to 6 weeks | Number of competing bidders and structure negotiation |
| Diligence and exclusivity | 8 to 14 weeks | Clinical chart review, billing audit, quality of earnings |
| Change of ownership and close | 8 to 20 weeks | CMS 855A processing, state licensure, accreditation transfer |
Two timing notes specific to hospice. Certificate-of-need states add review steps that can extend the licensure stage considerably. And in a change of ownership, the structure you choose determines whether the provider agreement transfers with its existing history and liabilities or the buyer enrolls fresh. That decision has real consequences for both parties, and it belongs in front of experienced healthcare counsel early rather than late.
Frequently asked questions about hospice buyers
Who buys hospice agencies most often in 2026?
Private-equity-backed strategic operators buy the most hospice agencies by deal count, followed by regional operators making tuck-in acquisitions. Roughly 41% of home health and hospice transactions in 2026 involved private equity capital in some form (Levin Associates, 2026).
Is my hospice too small to sell?
Agencies with as little as $1M to $3M in revenue sell regularly, usually to regional operators or as add-ons to a nearby platform. Size affects the multiple and the buyer pool, not whether a sale is possible.
What EBITDA multiple do hospice agencies sell for?
Hospice agencies have generally traded between 4.0x and 13.0x adjusted EBITDA as of August 2026, with Q2 2026 closed deals clustering at 9.0x to 13.0x and premium platforms above 14.0x. Your range depends on census stability, payer mix, cap headroom, survey history, referral concentration, and geography.
Should I respond to an unsolicited offer from a buyer?
You can respond, but avoid sharing financial detail or signing anything before you know your own value range and have confirmed the caller is a funded buyer rather than an intermediary gathering information. A single unsolicited offer gives you no basis for comparison.
Does the FY2027 hospice payment rule affect my valuation?
Indirectly, yes. The 2.3% update modestly improves forward revenue, while the quality-reporting penalty of -1.7% and the new Care Compare non-compliance icon make reporting discipline visible to buyers before diligence begins (CMS, 2026).
What is the hospice aggregate cap, and why do buyers care?
The aggregate cap limits total Medicare payment per beneficiary, set at $36,174.75 for the FY2027 cap year (CMS, 2026). Buyers care because an overage creates a repayment obligation, so agencies with thin cap headroom face closer scrutiny and sometimes escrow holdbacks.
Will a buyer keep my staff after the sale?
Clinical staff are usually retained because census depends on them, while back-office and administrative roles are the most likely to consolidate, particularly in platform integrations. Retention terms can be negotiated in the purchase agreement.
How do I find qualified hospice buyers without alerting my staff or referral sources?
A confidential process markets your agency under an anonymous profile, releases identifying information only after a buyer signs an NDA and demonstrates funding, and keeps your name out of the market until you choose to disclose it. That structure is the entire reason advisors exist in this space.
Start a confidential conversation
If buyers are calling, or you want to understand what your hospice would be worth before they do, we will walk through your numbers with you privately. No cost, no obligation, and nothing leaves the conversation. Vallexa works on 100% success-based fees, so we are only paid when a transaction closes.
Related resources
- Hospice M&A advisory: how we work with hospice owners from valuation through close.
- The 7 steps to selling: the full process, start to finish.
- Valuation calculator: an indicative range in a few minutes.
- Exits.ai: anonymous buyer mandates, useful if you want to see demand without revealing your agency.
- ExitStrategies.com: timing, succession, and exit planning.
- Approved.Loans: SBA and acquisition financing context, relevant when a smaller buyer needs funding to close.
- Earlier in this series: hospice valuation multiples, selling a hospice in Arizona, what buyers look for in a home health agency, and selling a home health agency to private equity.
Sources
- CMS, FY2027 Hospice Wage Index and Payment Rate Update Final Rule (CMS-1851-F) fact sheet, 2026.
- Federal Register, CMS-1851-F special filing, August 3, 2026.
- Hospice News, “Hospice M&A Valuations Ticking Upward,” May 2026.
- Home Health Care News, “Kinderhook Closes On Enhabit Acquisition,” May 2026.
- MedPAC, hospice payment adequacy analyses, 2026.
About the author
Jason Atty is the founder of Vallexa Advisors, a healthcare-only M&A advisory firm representing owners of home health, hospice, home care, and behavioral health businesses. Jason and the Vallexa team advise agency owners on valuation, pre-sale preparation, and confidential sale processes, working with a nationwide buyer network that includes private equity platforms, strategic operators, and regional acquirers. Vallexa operates on 100% success-based fees with no upfront charges, and maintains an NDA-gated process so that an owner’s identity is protected until they choose to disclose it.
Vallexa is part of an ecosystem that includes ValueMyBusiness.com, Exits.ai, and ExitStrategies.com.
Educational only. Not legal, financial, or tax advice. Healthcare M&A outcomes depend on specific facts, payer mix, market conditions, and regulatory context. Speak with qualified counsel before acting on anything in this document.
Last reviewed: August 10, 2026. Regulatory figures reflect the FY2027 hospice final rule effective October 1, 2026.
Key Takeaways
- The FY2027 Hospice Wage Index raises payments by 2.3%, impacting buyer perceptions and agency values.
- Private-equity-backed strategic platforms dominate hospice acquisitions, focusing on density and comprehensive management teams.
- Buyers evaluate agencies based on quality metrics like eligibility documentation, live discharge patterns, and compliance history.
- Hospice agencies typically trade between 4.0x and 13.0x EBITDA, with the exact multiple varying according to size and quality.
- Agencies can enhance their appeal by streamlining operations, diversifying referrals, and preparing for due diligence well in advance.
Estimated reading time: 13 minutes
